Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells

PLoS Pathog. 2020 Mar 20;16(3):e1008442. doi: 10.1371/journal.ppat.1008442. eCollection 2020 Mar.

Abstract

Latency reversal agents (LRA) variably induce HIV re-expression in CD4 T cells but reservoirs are not cleared. Whether HIV epitope presentation is similar between latency reversal and initial infection of CD4 T cells is unknown yet crucial to define immune responses able to detect HIV-infected CD4 T cells after latency reversal. HIV peptides displayed by MHC comes from the intracellular degradation of proteins by proteasomes and post-proteasomal peptidases but the impact of LRAs on antigen processing is not known. Here we show that HDAC inhibitors (HDCAi) reduced cytosolic proteolytic activities while PKC agonists (PKCa) increased them to a lesser extent than that induced by TCR activation. During the cytosolic degradation of long HIV peptides in LRA-treated CD4 T cells extracts, HDACi and PKCa modulated degradation patterns of peptides and altered the production of HIV epitopes in often opposite ways. Beyond known HIV epitopes, HDACi narrowed the coverage of HIV antigenic fragments by 8-11aa degradation peptides while PKCa broadened it. LRAs altered HIV infection kinetics and modulated CD8 T cell activation in an epitope- and time-dependent manner. Interestingly the efficiency of endogenous epitope processing and presentation to CD8 T cells was increased by PKCa Ingenol at early time points despite low levels of antigens. LRA-induced modulations of antigen processing should be considered and exploited to enhance and broaden HIV peptide presentation by CD4 T cells and to improve immune recognition after latency reversal. This property of LRAs, if confirmed with other antigens, might be exploited to improve immune detection of diseased cells beyond HIV.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigen Presentation*
  • Antigens, Viral / immunology*
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / pathology
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / pathology
  • HIV-1 / physiology*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Protein Kinase C / antagonists & inhibitors*
  • Protein Kinase C / immunology
  • Virus Latency / drug effects*
  • Virus Latency / immunology

Substances

  • Antigens, Viral
  • Histone Deacetylase Inhibitors
  • Protein Kinase C

Grants and funding

This study was funded by grants AI131912 and AI112493 from NIAID (https://www.niaid.nih.gov/) to SLG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.